Cytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals, clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan and other regions. The Company offers ECCO-50, a cure for knee osteoarthritis, which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50, a cure for urinary incontinence, which is in Phase II/III of development. The Company is also developing DCCT-10, a cure for cutaneous thermal injury.